Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2024-05-21 00:00:00 ET · period of report 2024-05-20 · accession 0000950170-24-063094 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-21 | 2024-05-20 | LAB | Black Jeffrey G. | SVP, CFO | A - Grant | $0.00 | +300.0K | 419.8K | +250% | $0 |
| D | 2024-05-21 | 2024-05-20 | LAB | Black Jeffrey G. | SVP, CFO | A - Grant | $0.00 | +400.0K | 400.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-20 | A | A | 300,000 | $0.00 | 419,836 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs") that vest as to 1/16th of the RSUs on August 20, 2024, with the remaining RSUs vesting in equally quarterly installments over four years thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-05-20 | A | A | 400,000 | $0.00 | 400,000 | D | $2.58 · — to 2034-05-20 | 400,000 Common Stock | (F2) The Option becomes exercisable as to 1/16th of the underlying shares on August 20, 2024, with the remaining shares vesting in equal quarterly installments over four years thereafter, subject to the Reporting Person's continued service through the applicable vesting date. |